Amgen’s Federal Circuit victory vindicates $13.4 billion Otezla IP acquisition
The company took a calculated risk by paying billions for drug while a slew of patent challenges were ongoing
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.